{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:31:08Z","timestamp":1773081068110,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Radioembolization (RE) is a viable therapy option in patients with intrahepatic cholangiocarcinoma (ICC). This study delineates a prognostic score regarding overall survival (OS) after RE using routine pre-therapeutic parameters. A retrospective analysis of 39 patients (median age, 61 [range, 32\u201382] years; 26 females, 13 males) with ICC and 42 RE procedures was conducted. Cox regression for OS included age, ECOG, hepatic and extrahepatic tumor burden, thrombosis of the portal vein, ascites, laboratory parameters and dose reduction due to hepatopulmonary shunt. Median OS after RE was 8.0 months. Using univariable Cox, ECOG \u2265 1 (hazard ratio [HR], 3.8), AST\/ALT quotient (HR, 1.86), high GGT (HR, 1.002), high CA19-9 (HR, 1.00) and dose reduction of 40% (HR, 3.8) predicted shorter OS (each p &lt; 0.05). High albumin predicted longer OS (HR, 0.927; p = 0.045). Multivariable Cox confirmed GGT \u2265 750 [U\/L] (HR, 7.84; p &lt; 0.001), ECOG &gt; 1 (HR, 3.76; p = 0.021), albumin \u2264 41.1 [g\/L] (HR, 3.02; p = 0.006) as a three-point pre-therapeutic prognostic score. More specifically, median OS decreased from 15.3 months (0 risk factors) to 7.6 months (1 factor) or 1.8 months (\u22652 factors; p &lt; 0.001). The proposed score may aid in improved pre-therapeutic patient identification with (un-)favorable OS after RE and facilitate the balance between potential life prolongation and overaggressive patient selection.<\/jats:p>","DOI":"10.3390\/cancers14215324","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T23:45:00Z","timestamp":1667087100000},"page":"5324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score"],"prefix":"10.3390","volume":"14","author":[{"given":"Imke","family":"Schatka","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans V.","family":"Jochens","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-6532","authenticated-orcid":false,"given":"Julian M. M.","family":"Rogasch","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"},{"name":"Berlin Institute of Health (BIH), Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-8351","authenticated-orcid":false,"given":"Thula C.","family":"Walter-Rittel","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"},{"name":"Department of Radiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-2737","authenticated-orcid":false,"given":"Uwe","family":"Pelzer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Benckert","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-1070","authenticated-orcid":false,"given":"Josefine","family":"Graef","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5664-7693","authenticated-orcid":false,"given":"Felix W.","family":"Feldhaus","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"},{"name":"Department of Radiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Gebauer","sequence":"additional","affiliation":[{"name":"Department of Radiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0657","authenticated-orcid":false,"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, 13353 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1072-7515(98)00203-8","article-title":"Aggressive surgical treatment of intrahepatic cholangiocarcinoma: Predictors of outcomes","volume":"187","author":"Roayaie","year":"1998","journal-title":"J. Am. Coll. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis","volume":"41","author":"Gill","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/fon-2017-0443","article-title":"Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma","volume":"14","author":"Filippi","year":"2018","journal-title":"Future Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/COC.0b013e3181f47583","article-title":"Radioembolization for the treatment of liver tumors general principles","volume":"35","author":"Kennedy","year":"2012","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s00259-019-04427-z","article-title":"Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: A multicenter study","volume":"46","author":"Levillain","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors: Description and possible risk factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","article-title":"Radioembolization-induced liver disease: A systematic review","volume":"29","author":"Braat","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1073274817729244","DOI":"10.1177\/1073274817729244","article-title":"Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"24","author":"Kis","year":"2017","journal-title":"Cancer Control."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Antkowiak, M., Gabr, A., Das, A., Ali, R., Kulik, L., Ganger, D., Moore, C., Abecassis, M., Katariya, N., and Mouli, S. (2019). Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. Cancers, 11.","DOI":"10.3390\/cancers11060879"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Damm, R., Seidensticker, R., Ulrich, G., Breier, L., Steffen, I.G., Seidensticker, M., Garlipp, B., Mohnike, K., Pech, M., and Amthauer, H. (2016). Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: Outcome assessment applying a predictive scoring system. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2549-x"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/JHC.S335879","article-title":"Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study","volume":"8","author":"Kim","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10620-021-06843-4","article-title":"A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC","volume":"67","author":"Nam","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Schatka, I., Tschernig, M., Rogasch, J.M.M., Bluemel, S., Graef, J., Furth, C., Sehouli, J., Blohmer, J.U., Gebauer, B., and Fehrenbach, U. (2021). Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. Cancers, 13.","DOI":"10.3390\/cancers13153777"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000517458","article-title":"A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy","volume":"40","author":"Nagel","year":"2022","journal-title":"Dig. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12149-015-0962-x","article-title":"Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy","volume":"29","author":"Soydal","year":"2015","journal-title":"Ann. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jvir.2020.06.027","article-title":"Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score","volume":"31","author":"Bargellini","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","article-title":"Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival","volume":"35","author":"Hoffmann","year":"2012","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma\u2014Evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2147\/OTT.S124161","article-title":"Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma","volume":"10","author":"Zhang","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.7314\/APJCP.2015.16.15.6255","article-title":"Model Based on Alkaline Phosphatase and Gamma-Glutamyltransferase for Gallbladder Cancer Prognosis","volume":"16","author":"Xu","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_25","first-page":"9","article-title":"Hepatoma-related gamma-glutamyl transferase in laboratory or clinical diagnosis of hepatocellular carcinoma","volume":"6","author":"Yao","year":"2007","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1097\/MEG.0b013e328364130f","article-title":"Elevation of serum \u03b3-glutamyltransferase as a predictor of aggressive tumor behaviors and unfavorable prognosis in patients with intrahepatic cholangiocarcinoma: Analysis of a large monocenter study","volume":"25","author":"Yin","year":"2013","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00432-016-2291-4","article-title":"Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: Preliminary results","volume":"143","author":"Jia","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.23818","article-title":"Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: Results from a pilot study","volume":"113","author":"Ibrahim","year":"2008","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00384-010-1113-4","article-title":"Low preoperative serum albumin in colon cancer: A risk factor for poor outcome","volume":"26","author":"Lai","year":"2011","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.7314\/APJCP.2015.16.14.5971","article-title":"Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group","volume":"16","author":"Tanriverdi","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_33","first-page":"62","article-title":"Serum albumin predicts survival in patients with hilar cholangiocarcinoma","volume":"5","author":"Waghray","year":"2017","journal-title":"Gastroenterol. Rep."},{"key":"ref_34","first-page":"749","article-title":"[Prognostic factors and long term outcome after surgery for hilar cholangiocarcinoma. Univariate and multivariate analysis]","volume":"56","author":"Ramacciato","year":"2004","journal-title":"Chir. Ital."},{"key":"ref_35","first-page":"161","article-title":"Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival","volume":"32","author":"Swinburne","year":"2017","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1435302","DOI":"10.1155\/2018\/1435302","article-title":"Transarterial Radioembolization (TARE) Agents beyond (90)Y-Microspheres","volume":"2018","author":"Bouvry","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/bjc.2016.191","article-title":"Yttrium-90 radioembolization for unresectable\/recurrent intrahepatic cholangiocarcinoma: A survival, efficacy and safety study","volume":"115","author":"Mosconi","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/RLU.0000000000000904","article-title":"Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma","volume":"40","author":"Edeline","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","article-title":"Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: Survival, efficacy, and safety study","volume":"36","author":"Rafi","year":"2013","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12149-015-1026-y","article-title":"Radioembolization with 90Y resin microspheres for intrahepatic cholangiocellular carcinoma: Prognostic factors","volume":"30","author":"Soydal","year":"2016","journal-title":"Ann. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13550-018-0419-z","article-title":"(90)Y-PET\/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer","volume":"8","author":"Levillain","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13550-017-0341-9","article-title":"Phantom validation of quantitative Y-90 PET\/CT-based dosimetry in liver radioembolization","volume":"7","author":"Pimpinella","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0009-8981(57)90027-X","article-title":"An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities","volume":"2","author":"Coltorti","year":"1957","journal-title":"Clin. Chim. Acta"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jvir.2010.10.029","article-title":"Research reporting standards for radioembolization of hepatic malignancies","volume":"22","author":"Salem","year":"2011","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1007\/s00330-022-08585-x","article-title":"Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: Predictive modeling strategies to anticipate tumor response and improve patient selection","volume":"32","author":"Kahn","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gibbs, P., Gebski, V., Van Buskirk, M., Thurston, K., Cade, D.N., and Van Hazel, G.A. (2014). Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-897"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer","volume":"34","author":"Hazel","year":"2016","journal-title":"J. Clin. Oncol.-N. Y."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Dutton, S.J., Kenealy, N., Love, S.B., Wasan, H.S., and Sharma, R.A. (2014). FOXFIRE protocol: An open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-497"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.115.165050","article-title":"Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients","volume":"57","author":"Fendler","year":"2016","journal-title":"J. Nucl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:26Z","timestamp":1760144726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/21\/5324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":50,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["cancers14215324"],"URL":"https:\/\/doi.org\/10.3390\/cancers14215324","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]}}}